PHEBRA yesterday announced
a new exclusive commercial
agreement with UK pharmaceutical
company Alliance Pharma PLc
to supply the Australian market
with obstetric drug Syntometrine
(oxytocin/ergometrine).
The medication is used as an
injection in the final stage of
labour to assist in the delivery
of the placenta and prevent
haemorrhaging, with Phebra to
undertake all sales and distribution
for Syntometrine in Australia after
winning a competitive tender
issued by Alliance Pharma.
Phebra ceo Mal Eutik said that
Syntometrine has “proven success
as a critical combination obstetric
drug and Phebra is pleased to be
making it available to the local
market”.The above article was sent to subscribers in Pharmacy Daily's issue from 25 Sep 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 25 Sep 13
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.